Eisai Press Release


Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
Jul 19, 2019 12:00 JST
Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat research data on Alzheimer's disease(AD).
More info..

Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
Jul 19, 2019 08:15 JST
Eisai Co.,Ltd. announced that data relating to a new anti-tau antibody E2814(1) was presented at the Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P4-696).
More info..

Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
Jul 18, 2019 13:26 JST
Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation.
More info..

Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
Jul 18, 2019 12:01 JST
Eisai Co.,Ltd. announced its latest data of nonclinical research which examined the effect to the synaptic function in the brain by spinal densities in regard to oral BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitor elenbecestat were presented at AAIC.
More info..

Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Jul 17, 2019 08:20 JST
Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration (NMPA).
More info..

Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
Jul 11, 2019 12:59 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002.
More info..

Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
Jul 11, 2019 09:04 JST
Eisai Co., Ltd. announced today that a total of 13 presentations containing two oral presentations including the latest data of the anti-amyloid beta (A beta) protofibril antibody BAN2401 and the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat, will be given at the Alzheimer's Association International Conference (AAIC) 2019..
More info..

Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
Jul 10, 2019 12:27 JST
Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.
More info..

Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
Jul 08, 2019 09:31 JST
Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area.
More info..

Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
Jun 18, 2019 12:32 JST
Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi's group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin.
More info..

Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress
Jun 18, 2019 12:11 JST
Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand.
More info..

Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 29, 2019 09:05 JST
Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleepwake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States.
More info..

"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 17, 2019 15:34 JST
Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction.
More info..

Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16, 2019 07:37 JST
Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan.
More info..

Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10, 2019 12:34 JST
Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan. Medac will submit a manufacturing and marketing authorization application for the product after conducting a clinical study in Japan.
More info..

Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 10, 2019 11:55 JST
These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai.
More info..

Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 09, 2019 11:33 JST
Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care.
More info..

Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
May 09, 2019 11:06 JST
Eisai Co., Ltd. announced today that the company has commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with those businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.
More info..

Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
May 08, 2019 08:37 JST
Eisai Co., Ltd. and the UK Dementia Research Institute (UK DRI) announced today the launch of a joint post-doctoral programme to support the advancement of novel dementia research.
More info..

Eisai Buys Out Purdue Rights to End Collaboration
May 01, 2019 08:09 JST
Eisai group will solely conduct the development and the commercialization of lemborexant globally.
More info..

Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
Apr 24, 2019 16:53 JST
Eisai Co., Ltd. has announced that the latest data on its dual orexin receptor antagonist lemborexant and its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 2019 Annual American Academy of Neurology (AAN) Meeting to be held from May 4 to 10, 2019 in Philadelphia, Pennsylvania in the United States.
More info..

Eisai Selected as Competitive ICT Strategy Company for 2019
Apr 24, 2019 08:36 JST
Eisai Co., Ltd. has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Competitive IT Strategy Company 2019 as a company that is engaged in the strategic utilization of IT.
More info..

Eisai: Japan MHLW Grants Sakigake Designation to Novel Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor E7090
Apr 08, 2019 13:06 JST
Eisai Co., Ltd. has announced that its in-house discovered fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor E7090 has been granted the SAKIGAKE designation by Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable biliary tract cancer with FGFR2 gene fusion.
More info..

Eisai to Launch Chocola BB Sparkling Kiwi & Lemon Flavor
Apr 08, 2019 10:43 JST
Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims, in Japan on Tuesday, April 9.
More info..

Eisai to Launch "Travelmin Support" as Series' First Quasi-Drug
Apr 05, 2019 09:45 JST
Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday, April 8.
More info..

Eisai: Data Safety Monitoring Board Recommends Continuation of Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
Mar 29, 2019 10:46 JST
Eisai Co., Ltd. announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in early Alzheimer's disease (AD).
More info..

Eisai's Initiation of Phase III Clinical Trial of BAN2401 in Early Alzheimer's Disease
Mar 22, 2019 10:37 JST
Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc.
More info..

Eisai to Present Latest Research on Alzheimer's Disease / Dementia Pipeline at the 14th International Conference on Alzheimer's & Parkinson's Diseases
Mar 22, 2019 10:23 JST
Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat will be given at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD).
More info..

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease
Mar 21, 2019 23:25 JST
Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia.
More info..

Latest Release


More Latest Release >>